Elizabeth Stansell Church
About Elizabeth Stansell Church
Elizabeth Stansell Church serves as the Deputy Director of the Therapeutics Research Program at the National Institutes of Health, overseeing over 70 clinical trials aimed at developing new treatments for diseases such as HIV, TB, and Hepatitis.
Work at National Institutes of Health
Elizabeth Stansell Church serves as the Deputy Director of the Therapeutics Research Program at the National Institutes of Health (NIH) in Bethesda, Maryland. In this role, she oversees a portfolio of more than 70 active clinical trials. These trials focus on developing new therapeutics and diagnostics for diseases such as HIV, tuberculosis (TB), and Hepatitis. Her leadership contributes to advancing research efforts aimed at addressing significant public health challenges.
Education and Expertise
Elizabeth Stansell Church earned her Bachelor of Arts (B.A.) in Chemistry from DePauw University, where she studied from 1996 to 2000. She then pursued a Ph.D. in Microbiology at the University of Alabama at Birmingham, completing her studies from 2000 to 2006. Her academic background provides a strong foundation for her work in therapeutics research, emphasizing her expertise in microbiology and chemistry.
Background
Before her current position at the NIH, Elizabeth Stansell Church worked as a Postdoctoral Fellow at Harvard Medical School from 2006 to 2013. This experience allowed her to further develop her research skills and knowledge in the field of therapeutics. Her career trajectory reflects a commitment to advancing medical research and improving health outcomes.
Achievements in Research Management
In her role at the NIH, Elizabeth Stansell Church specializes in conceptualizing and implementing quality initiatives that advance high-priority research projects. She is experienced in interest-based negotiations, which enhances collaboration and motivation within research teams. Her management skills contribute to the effective execution of clinical trials and the development of innovative therapeutic solutions.